Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies. We offer comprehensive evidence-generation solutions that combine medical imaging, eCOA, precision motion, cardiac and respiratory endpoints. For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have been deployed over 26,000 times to support clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012. For more information, go to Clario.com or follow us on LinkedIn.
CancerX
CancerX is the leading community to bring the power of digital and AI innovation in oncology, by accelerating their adoption through collaboration, community, and impactful initiatives. CancerX harnesses public-private partnerships to accelerate innovative digital solutions that improve cancer care effectiveness and reduce cancer’s burden for all people.
Burna Ai
Burna AI is a clinical intelligence platform that uses AI to automate CTCAE adverse event grading and streamline oncology workflow by reading clinical notes, labs, and patient data to deliver accurate, evidence-cited adverse event assessments in seconds. Built for cancer care teams, clinical trials, and oncology practices, it improves consistency, saves time, and enhances documentation quality.
BTBC Oncologic
BTBC Oncologic, Inc. develops OncoSol Prime™, a governed AI host‑modulation system that builds a “medical digital clone” for each patient. By forecasting health risks and generating personalized protocols, it reduces toxicity and hospitalizations—saving payers money. Our validated platform also serves as a reimbursable clinical decision‑support tool and a clinical trial endpoint. We are ready for clinical deployment and strategic partnerships.
Broncus Medical, Inc.
Broncus Medical, the leader in virtual bronchoscopic navigation, has developed Archimedes™ total lung access platform, including BTPNA – Bronchoscopic Trans-Parenchymal Nodule Access. The Archimedes® Navigation System integrates CT and fused fluoroscopy to provide 3D, real-time Guided Transbronchial Needle Aspiration (TBNA) and Bronchoscopic Trans-Parenchymal Nodule Access (BTPNA). The system combines nodule, vessel and airway mapping technology to ensure a safe and efficient Guided TBNA or BTPNA procedure. Archimedes is the only navigation system that provides multiple bronchoscopic techniques to access a nodule regardless of size, location or the presence of a bronchus sign. Broncus Medical is proud to introduce next generation pulmonary technology from access, diagnose to treatment.
Boston Medical Products
Boston Medical Products is the exclusive US distributor of NOVATECH brand products, such as the DUTAU® Rigid Bronchoscope, ROTEPS® Bronchoscopy Forceps, TONN™ stent applicators, SURVAC™ Suction Catheters, DUMON® stents and STERITALC®, (talc) powder, for intrapleural use, indicated to decrease recurrence of malignant pleural effusions and pneumothorax. ATS 2025 will be the OFFICIAL launch of the DUTAU® Rigid Bronchoscope as well as featuring the ROTEPS® Bronchoscopy Forceps.
Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. To deliver on our mission to transform patient care and improve outcomes through personalized diagnostics, we provide advanced diagnostic tests and custom diagnostic development services. | Biodesix is a leading diagnostic solutions and services company with a focus in lung disease. Biodesix offers five Medicare-covered tests for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment testing portfolio evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ portfolio supports treatment decisions across all stages of lung cancer with results in an average of two to three business days, expediting the time to treatment. For more information, www.biodesix.com.